Finanzen von Pliant Therapeutics Inc (PLRX)PLRXPliant Therapeutics Inc

Evaluating the bottom line, Pliant Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -50.29%, provide a clear picture of how effectively PLRX converts its operational activities into shareholder value.

In the context of the broader market, PLRX competes directly with industry leaders such as HYFT and HRTX. With a market capitalization of $49.93M, it holds a significant position in the sector. When comparing efficiency, PLRX's gross margin of N/A stands against HYFT's 58.58% and HRTX's 69.28%. Such benchmarking helps identify whether Pliant Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Pliant Therapeutics has reported consistent losses, with a net income loss of $23.577 million in Q4 2025 and a gross profit of $0.00 in multiple quarters, indicating financial struggles. The current ratio is strong at 9.90, suggesting good short-term liquidity, but the overall financial health remains concerning due to persistent losses.